Cargando…
Targeted therapies in rheumatoid arthritis: Focus on rituximab
B-cell depletion is a new strategy for treating patients with rheumatoid arthritis (RA). In the past years, several studies have proven the efficacy of anti-CD20 mediated B-cell depletion with rituximab (Mabthera(®)) in RA patients who failed TNF-blocking therapy. The important role of B-cells in th...
Autores principales: | Teng, YKO, Huizinga, TWJ, van Laar, JM |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721296/ https://www.ncbi.nlm.nih.gov/pubmed/19707303 |
Ejemplares similares
-
Rituximab for Rheumatoid Arthritis
por: Cohen, Marc D., et al.
Publicado: (2015) -
Rituximab for the treatment of rheumatoid arthritis: an update
por: Mok, Chi Chiu
Publicado: (2013) -
B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis
por: Tuscano, Joseph M, et al.
Publicado: (2009) -
Autoantibodies to GPI are predominantly present in extra-articular complications of human rheumatoid arthritis
por: van Gaalen, FA, et al.
Publicado: (2003) -
Rituximab therapy in Greek patients with rheumatoid arthritis
por: Tsiakalos, Aristotelis P, et al.
Publicado: (2008)